Notably, the Src kinase and MAPK pathways are common downstream effectors in lung, breast, and prostate cancers despite the variations in the predominant nAChR subunits in each cancer: α7 in lung, α9 in breast, and likely α5 and α7 in prostate tumors. This evidence concerns the gene CHRNA4 and Familial prostate cancer.